In pediatric patients <12 years, bioequivalence between the oral tablet and suspension has not been determined; due to possible shortened gastric transit time in infants and children, absorption of tablets may be different than adults
IV formulation contains sulfobutyl ether beta-cyclodextrin (SBECD) which may accumulate in renal insufficiency.
Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (discuss with ID). Target trough 1-5 mg/L. Collect in heparinized tube 0-30 minutes prior to dose and send to Toronto Sick Kids for analysis: http://www.sickkids.ca/paediatriclabmedicinems/test-catalogue/TDM/56312.html
Steady state should be achieved after 4-7 days.
*Use IV voriconazole with caution if creatinine clearance <50 mL/min (IV vehicle; SBECD (sulfobutylether-β-cyclodextrin) may accumulate)
Monitor QTc interval in patients at elevated risk
Monitor liver enzymes and bilirubin once weekly for first month and then monthly thereafter.
Hepatic enzyme abnormalities
Rash - up to 20%
Photosensitivity and photoxicity
Visual disturbances may occur
Many via CYP450- suggest review interactions with pharmacist.
Risk when combining with other QTc prolonging agents
Concentration: 40 mg/mL
Not all strengths of oral liquids are listed nor are available on IWK formulary
50 mg tablet
200 mg tablet
Tablets and capsules are preferred especially over an unpleasant tasting liquid.
Not all strengths of oral tablets/capsules are listed and they are not all available on the IWK formulary.
Antimicrobial class: Triazole antifungal, second generation
Average serum half life: Variable and dose dependent.
Route of Elimination: Urine (<2% as unchanged drug)